126 related articles for article (PubMed ID: 12932234)
1. Tyrosine phosphate in melanoma progression.
McArdle L; Bergin O; Fallowfield ME; Dervan PA; Easty DJ
Br J Dermatol; 2003 Aug; 149(2):289-95. PubMed ID: 12932234
[TBL] [Abstract][Full Text] [Related]
2. Microarray analysis of phosphatase gene expression in human melanoma.
McArdle L; Rafferty MM; Satyamoorthy K; Maelandsmo GM; Dervan PA; Herlyn M; Easty DJ
Br J Dermatol; 2005 May; 152(5):925-30. PubMed ID: 15888148
[TBL] [Abstract][Full Text] [Related]
3. Protein tyrosine kinases in malignant melanoma.
Easty DJ; Bennett DC
Melanoma Res; 2000 Oct; 10(5):401-11. PubMed ID: 11095400
[TBL] [Abstract][Full Text] [Related]
4. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
5. Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas.
Glaessl A; Bosserhoff AK; Buettner R; Hohenleutner U; Landthaler M; Stolz W
Arch Dermatol Res; 1999; 291(2-3):81-7. PubMed ID: 10195394
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value.
Väisänen A; Tuominen H; Kallioinen M; Turpeenniemi-Hujanen T
J Pathol; 1996 Nov; 180(3):283-9. PubMed ID: 8958806
[TBL] [Abstract][Full Text] [Related]
7. Micro-anatomy related antigen expression in melanocytic lesions.
Meije CB; Mooi WJ; Le Poole IC; Van Muijen GN; Das PK
J Pathol; 2000 Apr; 190(5):572-8. PubMed ID: 10727983
[TBL] [Abstract][Full Text] [Related]
8. Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions.
Georgieva J; Sinha P; Schadendorf D
J Clin Pathol; 2001 Mar; 54(3):229-35. PubMed ID: 11253137
[TBL] [Abstract][Full Text] [Related]
9. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
10. Loss of beta-catenin expression associated with disease progression in malignant melanoma.
Kageshita T; Hamby CV; Ishihara T; Matsumoto K; Saida T; Ono T
Br J Dermatol; 2001 Aug; 145(2):210-6. PubMed ID: 11531781
[TBL] [Abstract][Full Text] [Related]
11. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
12. Melanoma-associated expression of transforming growth factor-beta isoforms.
Van Belle P; Rodeck U; Nuamah I; Halpern AC; Elder DE
Am J Pathol; 1996 Jun; 148(6):1887-94. PubMed ID: 8669474
[TBL] [Abstract][Full Text] [Related]
13. Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours.
Sanders DS; Blessing K; Hassan GA; Bruton R; Marsden JR; Jankowski J
Mol Pathol; 1999 Jun; 52(3):151-7. PubMed ID: 10621837
[TBL] [Abstract][Full Text] [Related]
14. Expression of 12-lipoxygenase as a biomarker for melanoma carcinogenesis.
Winer I; Normolle DP; Shureiqi I; Sondak VK; Johnson T; Su L; Brenner DE
Melanoma Res; 2002 Oct; 12(5):429-34. PubMed ID: 12394183
[TBL] [Abstract][Full Text] [Related]
15. Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma.
Fang D; Hallman J; Sangha N; Kute TE; Hammarback JA; White WL; Setaluri V
Am J Pathol; 2001 Jun; 158(6):2107-15. PubMed ID: 11395388
[TBL] [Abstract][Full Text] [Related]
16. In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers.
Bosserhoff AK; Moser M; Hein R; Landthaler M; Buettner R
J Pathol; 1999 Mar; 187(4):446-54. PubMed ID: 10398105
[TBL] [Abstract][Full Text] [Related]
17. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
[TBL] [Abstract][Full Text] [Related]
18. c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas.
Funasaka Y; Boulton T; Cobb M; Yarden Y; Fan B; Lyman SD; Williams DE; Anderson DM; Zakut R; Mishima Y
Mol Biol Cell; 1992 Feb; 3(2):197-209. PubMed ID: 1372524
[TBL] [Abstract][Full Text] [Related]
19. A receptor-type protein tyrosine phosphatase PTP zeta is expressed in human cutaneous melanomas.
Goldmann T; Otto F; Vollmer E
Folia Histochem Cytobiol; 2000; 38(1):19-20. PubMed ID: 10763119
[TBL] [Abstract][Full Text] [Related]
20. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
